Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1038)	7/17/1998 12:24:00 PM
From: Ariella	Read Replies (1) \| Respond to of 1491

Thanks a lot for that detailed response. The second possibility -- that they could increase speed of trials -- is most interesting since, to avoid more stock sale, we need to have in place some progress payment with a partner before Q1 1999. That's not so far off. That they might have found a good dosage level already and are just fine-tuning is even more compelling. Regards, Ariella

To: NeuroInvestment who wrote (1038)	7/17/1998 11:42:00 PM
From: Rick Strange	Respond to of 1491

I think that some royalty payments have been made in advance so the net-net from revenue may be higher than NeuroInvestmeny has suggested. Seems to me that in the last 10-K or 10-Q there was a notation about making advanced royalty payments to the inventor and that he also happened to be on the Board. If this is the case then those advances should be deducted from future revenue. I'd look it up except I've the a summer flu bug or something and I'm going to crash and burn. If anyone has any energy...have at it.

To: NeuroInvestment who wrote (1038)	7/18/1998 8:35:00 PM
From: ROBERT M. SILVER	Read Replies (2) \| Respond to of 1491

Finally someone got it right on the $900,000. It is definitely a gross amount but they did not actually receive $900,000. BOL withheld the amount due them on the repayment of the $5,000,000. This came from the man who received the money from Pharmos. Dont think he would fabricate this item. He was the one who told me the money would be booked in the second quarter, when Gwyn the P.R. person was telling everybody it would not be recognized until the 3rd quarter.. I am not as technically minded as you sir, so cannot comment on why the dosage has been reduced in the latest group of patients. Your analysis sounds logical, company just trying to cover all bases getting ready for phase 3. More importantly is the question on how much more drug needs to be put in the pipeline, and how much Pharmos will receive in the third quarter. My guess is that 3rd quarter receipts will approximate $2,000,000 to $2,500,000. That could permit the company to break even in the third quarter. As to the purchase of product, my source told me some time ago, that Pharmos has bought product sufficient for one year to fill the pipeline. This came out of the original $5 million loaned to them by BOL. They ship the raw product to BOL as needed etc. He also thought it was possible that July receivables from BOL may not equal the $900,000. received at the end of June. Reorders will become a factor and a function on the amount of RX's are written by the Doctors of this country. LIf the EU approves marketing of the drug, there will be a substantial pipeline to fill over there. If it goes country by country it will be slower. Perhaps some one on this thread knows if licensing in Europe is on a country by country basis or whether there can be one stop approvals out of Luxemburg or Belgium (Headquarters of the EU.) .Does anyone know if any product is sold in Israel? Hope the information has been informative. For any comments I can be reached at Willemspal@AOL.com Robert